Author:
Delecia R. Robinson, MD
Senior Medical Director, Laboratory Medicine (Molecular and Non-molecular)
eviCore Healthcare
Bluffton, South Carolina
Primary Audience:
Phlebotomists, Laboratory Technologists, Laboratory Directors
Author:
Delecia R. Robinson, MD
Senior Medical Director, Laboratory Medicine (Molecular and Non-molecular)
eviCore Healthcare
Bluffton, South Carolina
Primary Audience:
Phlebotomists, Laboratory Technologists, Laboratory Directors
Secondary Audience:
Pathologists, Clinical Scientists (Includes all sub-specialty areas), Students, Pathologist Assistants, Residents, and Students
Upon completion of this activity, you will be able to:
· briefly describe the workflow for next-generation sequencing of paraffin-embedded tumor samples;
· discuss several tumor mutations and the associated drug class that may (or may not) be used to treat them;
· contrast the clinical implications of monoallelic and biallelic MUTYH mutations;
· describe the testing required to determine whether a mutation identified by a next-generation sequencing tumor marker panel is a germline mutation; and
· discuss the increased cancer risks associated with MUTYH-associated polyposis hereditary cancer syndrome.